ITCI: Intra-Cellular Price to Sales
The implementation of "green chemistry" principles for environmental protection is complemented by basic compliance with laboratory waste disposal standards for Intra-Cellular Therapies (ITCI). The P/S ratio history on the GURU.Markets chart visualizes this process, where 20.60 serves as the current metric level. Business stability is supported by international biocomponent logistics and the diversification of research centers, ensuring high long-term profitability for the company.
Metric breakdowns and analytics for Intra-Cellular Therapies (ITCI)
- market price and analyst price targets:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Intra-Cellular Therapies|ITCI - Long-Term Debt to Equity|Short-Term Debt to Equity intracellulartherapies.com|ITCI - Company Aggregate Debts|Debts to Book Capitalization Intra-Cellular|ITCI - Company Long-Term Debt|Company Short-Term Loans and Borrowings Intra-Cellular Therapies|Intermediate Coverage Ratio intracellulartherapies.com
- financial results and valuation multiples details:
ITCI - Net Income|Future Net Profit Intra-Cellular Therapies|ITCI - P/E Multiple|Future Price to Earnings Multiple intracellulartherapies.com|ITCI - PEG Multiple|Company Value to EBITDA Intra-Cellular|ITCI - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Intra-Cellular Therapies|ITCI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth intracellulartherapies.com|ITCI - Earnings per share growth in current year|Net earnings per share change forecast for next year Intra-Cellular Therapies
- total revenue and sales volume data:
General company analysis:ITCI Intra-Cellular Therapies Inc.
The P/S multiple relates market capitalization to sales volume, reflecting investor expectations regarding the business's future sector share. Analyzing the divergence of the P/S from its historical average allows for the identification of asset overvaluation, which is critical for Intra-Cellular Therapies (ITCI), where the high stock price is justified by colossal R&D expenditures and the potential for leadership in neurobiology.
Competitors of Intra-Cellular Therapies
Market Cap to Revenue biogen.com BIIB|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Price to Sales|AXSM - Price-to-Revenue Ratio|ACAD: Price-to-Revenue Ratio|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|VKTX (vikingtherapeutics.com) - Price-to-Revenue Ratio|Market Cap to Revenue SUPN|P/S Multiple Catalyst Pharma|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Price-to-Revenue Ratio HRMY (Harmony Corp)|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PRAX (Praxis Precision Medicines Inc)|AVXL (Anavex Corp) - Market Cap to Revenue|CeriBell EEG - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PRTA|ALEC (Alector Therapeutics) - Market Cap to Sales Volume|P/S Multiple ANNX|OMER (omeros.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio NMRA (neumoratx.com)|SCLX: P/S Multiple|Tevogen Bio Holdings Inc. (TVGN) - P/S Multiple|Price-to-Revenue Ratio Alpha Cognition Inc|Cognition Therapeutics Inc. - Price-to-Sales Ratio|P/S Multiple IKT|Price-to-Revenue Coefficient cassavasciences.com|P/S Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Sales|VTGN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Ovid Therapeutics Inc. OVID|ABOS: P/S Multiple|CRVO - Price-to-Revenue Coefficient|Market Cap to Revenue ATHE|CLNN (Clene Nanomedicine) - Market Cap to Sales Volume|P/S Multiple PEPG|Market Cap to Revenue Jupiter Neurosciences, Inc. JUNS|P/S Multiple RLMD (Relmada Therapeutics)|Price-to-Revenue Coefficient annovisbio.com (ANVS)|GRCE - Price-to-Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|Price to Sales NeuroSense Therapeutics Ltd. (NRSN)|Market Cap to Revenue RVPH|P/S Multiple MetaVia, Inc.|Price-to-Revenue Ratio NeurAxis (NRXS)|HSDT (heliusmedical.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Price to Sales|Minerva Neurosciences - P/S Multiple|Price-to-Revenue Coefficient athira.com ATHA|Addex Therapeutics Ltd (ADXN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ALZN|Market Cap to Revenue CYCN|PTIX (Protagenic) - Market Cap to Sales Volume|Price-to-Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATXI (Avenue Therapeutics, Inc.)|P/S Multiple Brainstorm Cell Therapeutics Inc. BCLI|CARA: Market Cap to Revenue|Price-to-Revenue Multiple Chromocell (CHRO)|ELYM: P/S Multiple|Market Cap to Revenue longboardpharma.com|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales NKGen Biotech Inc NKGN|Price-to-Revenue Ratio NeuroBo (NRBO)|Price-to-Revenue Ratio SAGE (Sage Therapeutics Inc)|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|trevena.com - Price-to-Revenue Ratio|VIGL: Market Cap to Revenue|WENA - P/S Multiple|Cerevel (CERE) - Price-to-Revenue Ratio
